Piperacillin-Tazobactam Intravenous Dosage
For adults with normal renal function, the standard dose is 3.375 g IV every 6 hours (totaling 13.5 g daily), with higher doses of 4.5 g IV every 6 hours (totaling 18 g daily) reserved for nosocomial pneumonia or severe infections. 1
Adult Dosing by Indication
Standard Infections (Non-Pneumonia)
- Dose: 3.375 g (3 g piperacillin/0.375 g tazobactam) IV every 6 hours 2, 1
- Infusion time: 30 minutes standard, though extended infusion (3-4 hours) may improve outcomes 3
- Total daily dose: 13.5 g (12 g piperacillin/1.5 g tazobactam)
Nosocomial Pneumonia
- Dose: 4.5 g (4 g piperacillin/0.5 g tazobactam) IV every 6 hours 2, 1
- Combination: Plus an aminoglycoside for initial empiric therapy 2
- Total daily dose: 18 g (16 g piperacillin/2 g tazobactam)
Severe Infections/Sepsis
For critically ill patients with sepsis or infections caused by less susceptible organisms (MIC 8-16 mg/L), use 4.5 g every 6 hours with extended infusion (3-4 hours) or continuous infusion to maximize time above MIC. 3, 4 The Surviving Sepsis Campaign guidelines emphasize that extended infusion of β-lactams (over 3-4 hours rather than 30 minutes) increases the time that drug concentrations remain above the pathogen MIC, which is critical for optimal response in severe infections 3.
Multidrug-Resistant Organisms
For carbapenem-resistant Pseudomonas aeruginosa (CRPA) susceptible to piperacillin-tazobactam:
- Dose: 3-4 g piperacillin component IV every 6 hours 5
- Alternative: 3.375-4.5 g IV every 6 hours 5
- Duration: 5-14 days depending on infection site 5
Pediatric Dosing
Infants 2-9 Months
- Standard infections: 90 mg/kg (80 mg piperacillin/10 mg tazobactam) IV every 8 hours 1
- Nosocomial pneumonia: 90 mg/kg IV every 6 hours 1
Children >9 Months to 40 kg
- Standard infections: 112.5 mg/kg (100 mg piperacillin/12.5 mg tazobactam) IV every 8 hours 1
- Nosocomial pneumonia: 112.5 mg/kg IV every 6 hours 1
General Pediatric Dosing (Alternative Guidelines)
- Dose range: 60-75 mg/kg/dose of piperacillin component every 6 hours 2
- Alternative: 200-300 mg/kg/day of piperacillin component divided every 6-8 hours 6, 5
- Maximum: Do not exceed adult doses 5
Neonates
Postmenstrual age ≥30 weeks: 80 mg/kg/dose of piperacillin component IV every 6 hours 5 Postmenstrual age <30 weeks: 100 mg/kg/day divided every 8 hours 5
Renal Impairment Dosing
Dose reduction is required when creatinine clearance ≤40 mL/min 1:
- CrCl 20-40 mL/min: 2.25 g every 6 hours
- CrCl <20 mL/min: 2.25 g every 8 hours
- Hemodialysis: 2.25 g every 8 hours (with supplemental dose of 0.75 g after each dialysis session)
- CRRT: Dosing varies; consider 3.375 g every 8 hours with therapeutic drug monitoring
Infusion Strategy Considerations
Extended infusion (3-4 hours) is superior to standard 30-minute infusion for critically ill patients and infections with higher MICs. 3, 7 A landmark study demonstrated that extended-infusion piperacillin-tazobactam (3.375 g IV over 4 hours every 8 hours) reduced 14-day mortality from 31.6% to 12.2% (P=0.04) and shortened hospital stay from 38 to 21 days (P=0.02) in critically ill patients with APACHE-II scores ≥17 compared to intermittent infusion 7.
Continuous Infusion Option
For severe infections or augmented renal clearance:
- Loading dose: 3.375-4.5 g IV over 30 minutes
- Maintenance: 12-16 g/day as continuous infusion 3, 8
- This maintains steady-state concentrations consistently above MIC for susceptible pathogens
Important Clinical Caveats
Avoid underdosing in early sepsis: Critically ill patients exhibit increased volume of distribution and augmented renal clearance, leading to subtherapeutic levels with standard dosing 3. Consider higher initial doses (4.5 g every 6 hours) for the first 24-48 hours.
Neurotoxicity risk: Piperacillin has relatively low neurotoxicity compared to other β-lactams, but accumulation in renal failure can cause seizures 9. Monitor for neurological changes when trough concentrations exceed 360 mg/L 9.
De-escalation strategy: For community-acquired intra-abdominal infections, consider de-escalating from piperacillin-tazobactam to narrow-spectrum agents (e.g., ceftriaxone plus metronidazole) once cultures identify susceptible organisms 10. This reduces piperacillin-tazobactam exposure by approximately 1.2 days without increasing complications 10.
Combination therapy: When used for necrotizing infections, always combine with vancomycin for MRSA coverage 2. For nosocomial pneumonia, add an aminoglycoside initially 2, 1.